Barbara J Sahakian is Professor of Clinical Neuropsychology at the University of Cambridge Department of Psychiatry and MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute. She is also an Honorary Clinical Psychologist at Addenbrooke’s Hospital, Cambridge. She holds a PhD and a DSc from the University of Cambridge, is President of the International Neuroethics Society, Past-President of the British Association for Psychopharmacology and a Fellow of the Academy of Medical Sciences. Sahakian has an international reputation in the fields of psychopharmacology, neuropsychology, neuropsychiatry, neuroimaging and neuroethics. She is perhaps best known for her work on ‘hot’ and ‘cold’ cognitive deficits in depression and early detection and treatment with cholinesterase inhibitors in Alzheimer’s disease. She has over 390 publications in high impact scientific journals. The International Statistical Institute credits Sahakian with a (H) index of 100, with some publications having over 300 citations. Sahakian co-invented the neuropsychological CANTAB tests. She serves as a Senior Consultant to Cambridge Cognition, a University of Cambridge spin-out that provides CANTAB. She is also a Consultant for Peak (Brainbow). Sahakian has contributed to Neuroscience and Mental Health Government Policy and has spoken on resilience, brain health, neuroscience and mental health at the World Economic Forum, Davos, 2014. She is a member of the World Economic Forum Global Agenda Council on Brain Research. She was also a finalist for a World Technology Award 2014 under the category of 'Health and Medicine'.